| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net sales | 185,149 | - |
| Cost of sales | 52,800 | - |
| Gross profit | 132,349 | - |
| Selling expense | 37,272 | - |
| Marketing expense | 3,758 | - |
| Administrative expense | 21,268 | - |
| Finance expense | 8,322 | - |
| Management information systems expense | 2,043 | - |
| Research and development expense | 2,970 | - |
| Process engineering expense | 1,828 | - |
| Regulatory and clinical expense | 5,808 | - |
| Other (income) expense, net | -6,928 | - |
| Net income | 42,152 | 24,790 |
| Depreciation and amortization | 7,813 | 5,200 |
| Stock-based compensation | 5,730 | 3,990 |
| Amortization of issuance costs on convertible senior notes | 653 | - |
| Provision for inventory write-downs | 1,893 | 1,030 |
| Provision for credit losses | 455 | 337 |
| Fair value adjustments to contingent consideration obligations | 0 | 0 |
| Foreign currency transaction effect on income | 79 | 279 |
| Accounts receivable | 1,403 | 5,299 |
| Inventory and other deferred costs | 6,805 | - |
| Prepaid expenses and other assets | -1,639 | -1,676 |
| Non-cash interest expense and end of term accretion expense | - | 2,589 |
| Accounts payable and other liabilities | 5,327 | -1,250 |
| Inventory and other deferred costs | - | 3,454 |
| Accrued interest | 719 | - |
| Net cash provided by operating activities | 58,094 | 29,330 |
| Purchases of short-term marketable securities | 43,015 | 17,849 |
| Purchases of property and equipment | 5,006 | 2,725 |
| Payments related to acquisitions, net of cash acquired | 95 | 95 |
| Net cash used in investing activities | -48,116 | -20,669 |
| Proceeds from stock option exercises | 4,657 | 3,072 |
| Deferred payments for acquisitions | 1,433 | 1,433 |
| Payment of withholding taxes in connection with net settlement of equity awards | 605 | 605 |
| Common stock cash dividend paid | 13,572 | 9,037 |
| Net cash (used in) provided by financing activities | -10,953 | -8,003 |
| Effect of exchange rate changes on cash and cash equivalents | 859 | 909 |
| Net increase (decrease) in cash and cash equivalents | -116 | 1,567 |
| Cash and cash equivalents at beginning of period | 25,610 | - |
| Cash and cash equivalents at end of period | 25,494 | - |
LEMAITRE VASCULAR INC (LMAT)
LEMAITRE VASCULAR INC (LMAT)